Related Experiment Video
Updated: Jan 30, 2026

Multipronged Phenotyping Approaches to Characterize Sugarcane Root Systems
Published on: August 17, 2022
Novel Approaches for Systemic Mastocytosis
Luke Fletcher1,2, Uma Borate1,2
1Knight Cancer Institute.
Purpose Of Review:
The purpose of this review is to summarize the pathophysiology of systemic mastocytosis, review the most recent clinical trials and drug development in systemic mastocytosis, with a specific focus on the advanced systemic mastocytosis subtypes.
Recent Findings:
Systemic mastocytosis is a clonal neoplasm of mast cells that has had a number of successful therapeutic options being developed in the past few years. The first therapeutic agent to be Food and Drug Administration (FDA) approved in decades was midostaurin in 2017 with a 60% response rate % with improvement in both end-organ damage and symptoms. However, complete responses/remissions with midostaurin have been elusive. Additional clinical trials of tyrosine kinase inhibitors that target the proto-oncogene receptor tyrosine kinase (KIT) mutation show great promise. The two drugs with promising early clinical trial data include avapritinib and DCC-2618 with avapritinib showing potential to induce complete remissions.
Summary:
Therapies for systemic mastocytosis are in a stage of evolution with further elucidation of additional mutations associated with oncogenesis in addition to the most commonly described KIT (give details), ongoing clinical trials could potentially with lead to further targeted therapy and increased complete responses and durable remissions.
Insights
New therapies are evolving for advanced systemic mastocytosis, a rare blood cancer. While midostaurin offers some improvement, newer tyrosine kinase inhibitors show promise for complete remission in systemic mastocytosis patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Systemic mastocytosis is a rare clonal neoplastic disease of mast cells.
- Recent advancements have introduced novel therapeutic agents targeting specific mutations.
Purpose of the Study:
- To review the pathophysiology of systemic mastocytosis.
- To summarize recent clinical trials and drug development for systemic mastocytosis, focusing on advanced subtypes.
Main Methods:
- Literature review of recent clinical trials and drug development in systemic mastocytosis.
- Focus on targeted therapies, particularly tyrosine kinase inhibitors.
Main Results:
- Midostaurin, FDA-approved in 2017, shows a 60% response rate but limited complete remissions.
- Avapritinib and DCC-2618, targeting KIT mutations, demonstrate promising early clinical trial data, with avapritinib showing potential for complete remissions.
Conclusions:
- Systemic mastocytosis therapies are rapidly evolving.
- Further research into oncogenic mutations and targeted therapies may improve complete response rates and durable remissions.
Related Concept Videos
Second Order systems II
First Order Systems
When a first-order system is subjected to a unit-step input, its response is characterized by its transfer function. By applying the Laplace transform of the unit-step input to the transfer function, expanding the...
Second Order systems I
By reinterpreting the system, one can derive the closed-loop transfer function, which...
Thermodynamic Systems
Consider an example of tea boiling in a kettle. The...
Classification of Systems-I
Homogeneity dictates that if an input x(t) is multiplied by a constant c, the output y(t) is multiplied by the same constant. Mathematically, this is expressed as:
Classification of Systems-II

